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The Healthcare Infection Control Practices Advisory Committee (HICPAC) is a 
federal advisory committee made up of 14 external infection control and public health 
experts who provide guidance to the Centers for Disease Control and Prevention (CDC) 
and the Secretary of the Department of Health and Human Services (DHHS) regarding 
the practice of healthcare infection prevention and control, strategies for surveillance, 
and prevention and control of healthcare associated infections (HAIs) in United States 
healthcare facilities.  As such, one of the primary functions of the committee is to issue 
recommendations for preventing and controlling HAIs in the form of guidelines and less 
formal communications.1, 2  Currently, HICPAC guidance documents are available on its 
website for download 1, and a number of additional documents have been published 
since HICPAC's inception, most commonly in Morbidity and Mortality Weekly Report 
(MMWR), Infection Control and Hospital Epidemiology (ICHE), and the American 
Journal of Infection Control (AJIC).   
The strength of the HICPAC guidance documents stem from their process of 
development as well as their content and organization.  HICPAC's processes were set 
in motion at the time of its creation by the Secretary of DHHS in 1991.  The committee 
was organized at the request of CDC to provide a setting for guideline development that 
was free from political or financial influence and that enabled multidisciplinary and public 
input.  Members are recommended by CDC and appointed by the Secretary of DHHS 
from experts in the fields of infectious diseases, healthcare associated infections, 
nursing, surgery, epidemiology, public health, health outcomes and related areas of 
expertise.  In fact, the Federal Advisory Committee Act mandates that membership 
include individuals with a variety of interests, backgrounds and expertise.  All HICPAC 
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members are required to regularly disclose potential conflicts of interest.  The 
committee also has ex officio members like the Agency for Healthcare Research and 
Quality as well as liaisons from professional organizations like the Association for 
Professionals in Infection Control and Epidemiology Inc., and the Society for Healthcare 
Epidemiology of America.  Other such non-voting representatives are included as the 
Secretary deems necessary to carry out the functions of the Committee effectively.   
Since the creation of HICPAC, guidelines have been drafted by CDC in collaboration 
with outside experts, reviewed and revised within HICPAC, and published in the Federal 
Register for public comment before final publication.1-3   
The content and organization of HICPAC's guidance documents include: 1) a 
thorough yet concise review of the guideline topic and 2) a recommendations section 
which communicates strength of recommendations as well as supporting evidence 
grades.  This structure has enabled the committee to differentiate those practices for 
which the available scientific evidence provides strong support or rejection (Category I) 
from those practices where there is only suggestive or less definitive evidence 
(Category II).  The grading of the evidence behind the recommendation has also 
allowed the committee to differentiate strong recommendations with a firm scientific 
foundation (Category IA) from strong recommendations with a weaker scientific 
foundation (Category IB).  The more recent introduction of Category IC 
recommendations has enabled a further distinction of strong recommendations 
mandated by federal and/or state statutes, regulations or standards. 
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The value of HICPAC documents is reflected in their use by individual infection 
preventionists and healthcare epidemiologists 4, as well as national societies committed 
to infection prevention and control5.  In addition, the value of HICPAC documents is 
reflected in a growing body of evidence suggesting they enhance the quality and safety 
of patient care 6-10.  For example, Manangan and others demonstrated an association 
between a high level of awareness and adoption of HICPAC recommendations with a 
decrease in the incidence of ventilator-associated pneumonia (VAP) among 188 
hospitals.10  Likewise, almost 90% of direct care providers were aware of 
recommendations in CDC’s Hand Hygiene Guideline, and increased adherence with 
these recommendations correlated with a lower incidence of central line-associated 
bloodstream infections (CLABSI).7  Several other recent investigations have provided 
indirect evidence that HICPAC recommendations applied in “bundles” can result in 
significant reductions in the incidence of CLABSI.6, 8, 9 
Strengthening HICPAC Guidelines to Address Emerging Needs 
Despite the strengths of HICPAC's guidance documents and the processes used 
in their development, a number of recent advances in guideline development and 
implementation have emerged that offer HICPAC an opportunity to further strengthen 
the validity and impact of their guidelines.  Many of these advances have been 
integrated into the guideline development processes of societies on the forefront of 
guideline development, providing HICPAC with excellent models for updating its 
guideline methodology.11-16  Advances in guideline development and implementation 
have also been promoted by authors, committees, and organizations focused on 
improving the validity and usability of guidelines.17-21  
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Importantly, these advances also allow HICPAC to address emerging challenges 
in guideline development in the area of infection prevention and control.  Such 
challenges include: 1) an immense and rapidly growing evidence base that makes it 
more important than ever to utilize strategies that allow one to efficiently locate and use 
the most valid and clinically relevant studies available; 2) emerging infections for which 
infection preventionists require guidance yet for which there is little evidence on which 
to base recommendations; 3) increasing attention to infection prevention and control by 
surveyors, regulatory agencies, government and commercial payors in the United 
States and abroad, making the need for rigorous evidence-based guidelines more 
pressing 22, 23; and 4) escalating quantity of guidelines available to guide care on any 
given topic, which makes clear communication, recommendation bundles, and 
implementation plans key to any guideline’s success 24, 25.  In addition, the threats of 
commercial and political bias are as important now as they were at the time HICPAC 
was created, particularly with the potential financial benefits to industry of guideline 
endorsements21, 26, and the challenge that payors and healthcare facilities have to 
improve the value of their healthcare dollar.   
Given these challenges, the needs of HICPAC are clear.  The committee must: 
1) create the processes necessary to rapidly develop and update guidelines to allow an 
appropriate response to emerging needs and new scientific evidence; 2) address the 
key clinical questions of infection preventionists and providers in a targeted way; 3) use 
the best available evidence to answer those questions efficiently; 4) provide transparent 
recommendations without bias; and 5) prioritize recommendations for implementation.  
This document provides an update on the methods used by HICPAC to address these 
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needs.  Specifically, we describe how HICPAC is using emerging methods in guideline 
development to create guidelines based on targeted systematic reviews of the best 
available evidence, with explicit links between the evidence and recommendations, 
which can be efficiently updated and provide priorities for practitioners as well as future 
research agendas.  We also discuss methods used to enhance the reach and impact of 
these guidelines on the quality, safety and value of patient care.  These methodologies 
are approved by HICPAC and will be used for subsequent guidelines issued by 
HICPAC, beginning with the Prevention of Catheter Associated Urinary Tract Infection 
Guideline, which was initiated in the Fall of 2007. 
Organizing to Accomplish Our Goals  
In order to reengineer its guideline development process, HICPAC first 
restructured its approach.  In its new approach, each guideline is developed by a 
working group in consultation with a panel of content experts and HICPAC (Figure 1).  
All funding is provided by CDC.  Financial conflicts of interest are vetted and disclosed 
for all working group, content experts, and HICPAC members.   
The working group has accountability for all phases of methodology, including 
development of the key questions around which the guideline is based, the systematic 
review of the evidence, and the guideline itself.  It also is responsible for providing 
content experts and HICPAC members with progress updates at agreed-upon dates.  
Each working group includes but is not limited to three main stakeholders: a HICPAC 
member, a staff member from CDC, and outside experts in the methodology of 
guideline development.  Each member has individual as well as overlapping 
accountabilities.   
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The HICPAC member is responsible for helping to develop the key questions, 
reviewing abstracts and full text articles for inclusion in the guideline, reviewing 
summaries of the evidence and the guideline recommendations, and communicating 
progress of the working group at regular HICPAC meetings, as well as communicating 
progress to and soliciting input from experts who are external to HICPAC.   
The CDC staff member comes from the Division of Healthcare Quality Promotion 
in the National Center for Preparedness, Detection and Control of Infectious Diseases, 
and responsibilities include helping to develop key questions, reviewing abstracts and 
full text for inclusion, and writing the evidence summaries and recommendations as well 
as the following guideline sections: the executive summary, summary of 
recommendations, implementation and audit, recommendations for further research and 
background.   
The experts in guideline methodology include a project manager, an analyst, and 
a medical librarian.  The role of the project manager includes developing and 
maintaining guideline methods, setting the timeline, and reviewing and integrating all 
aspects of guideline development.  The analyst extracts data from included studies, 
builds evidence tables, and grades the overall quality of the evidence for guideline 
questions using formal processes.  The librarian assists the working group in developing 
search strategies and choosing resources to find relevant references, run searches, and 
manage included and excluded references.  
The panel of content experts consists of three or more content experts both 
internal and external to HICPAC.  These experts are chosen at the discretion of 
HICPAC.  The expert panel participates and provides feedback in regular progress 
 10
updates, and provides in-depth reviews of key questions, the bibliography resulting from 
the initial literature search, the draft evidence report, and guideline recommendations.   
HICPAC members and liaisons participate in the guideline development process 
and provide feedback in regular progress updates, as well as on the draft evidence 
report and guideline recommendations.  HICPAC members then vote to approve the 
final guideline. 
The expertise and experience of relevant professional societies is also critical to 
this process.  As such, representatives of these societies can participate through 
multiple routes, including as HICPAC liaisons, content experts, or working group 
members. 
Methods in Guideline Development 
HICPAC guidelines are now based on targeted systematic reviews of the best 
available evidence. The Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) approach is used to provide explicit links between the available 
evidence and the resulting recommendations.27-30  The guideline development process 
is outlined in Figure 2. 
Development of Key Questions 
Each HICPAC guideline begins with the drafting and refining of the key questions 
most critical to infection prevention and control personnel and providers for the given 
guideline topic.  These questions then serve as a foundation for the guideline, and guide 
the systematic review of the evidence and the development of the guideline 
recommendations.  To develop the key questions, the working group first conducts a 
search of medical literature databases and websites for all relevant guidelines and 
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narrative reviews on the topic of interest, and then drafts key questions based on their 
review of these documents.  Databases commonly searched include MEDLINE and the 
National Guideline Clearinghouse.  Websites commonly searched include those of 
government technology assessment programs like the National Institute for Health and 
Clinical Excellence (NICE) in the United Kingdom 31, commercial payors like 
BlueCross/BlueShield in the United States 32, or federal or state websites in the United 
States.  Once a preliminary list of key questions is developed from an examination of 
the relevant guidelines and reviews identified in the search, the key questions are vetted 
and revised by the content experts, and then are presented to and finalized by HICPAC 
members.  
Literature Search 
Following the development of the key questions, search terms are developed for 
identifying the literature most relevant to those questions. For the purposes of quality 
assurance, these terms are compared to those used in relevant guidelines, reviews and 
seminal studies. These search terms are then incorporated into search strategies for the 
relevant electronic medical literature databases. Searches are commonly performed in 
MEDLINE, EMBASE, CINAHL and Cochrane, and the resulting references are imported 
into reference management software, where duplicates can be resolved. Cochrane 
reviews ultimately included in guidelines are checked for updates prior to completion of 
the first guideline draft.  
Study Selection 
 In general, a best available evidence approach is used to review articles for 
inclusion.  For example, if there are randomized controlled trials (RCTs) that address a 
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therapy question, then evidence lower in the evidence hierarchy may not considered.  
Inclusion and exclusion criteria that are general or specific to individual key questions 
are developed and used to review references, starting with titles and abstracts.  Full text 
articles are reviewed using the same criteria and are retrieved if they meet inclusion 
criteria.  Studies that are commonly included are those that are: 1) relevant to one or 
more key questions, 2) primary analytic research, a systematic review or meta-analysis, 
and 3) written in English. Disagreements between reviewers regarding whether an 
individual study meets inclusion/exclusion criteria are resolved by consensus of those 
reviewers.   
Data Extraction and Synthesis 
For those studies meeting inclusion criteria, data relevant to the evidence review 
and guideline development is extracted into evidence tables.  This data commonly 
includes: the study author, year, design, quality, objective, population, setting, sample 
size, power, follow-up, and definitions and results of clinically relevant outcomes.  
Evidence tables are developed for each key question, with study data being extracted 
into the relevant evidence tables. Then, studies are organized by the common themes 
that emerge within each evidence table. Data are extracted by one or more authors, and 
disagreements are resolved by the remaining authors. Data and analyses are most 
often extracted as originally presented in the included studies. Meta-analyses are 
performed only where their use is deemed critical to a recommendation and only in 
circumstances where multiple studies with sufficiently homogenous populations, 
interventions, and outcomes can be analyzed. Systematic reviews may also be included 
in a guideline if there are a large number of relevant reviews available in the literature.33  
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Otherwise, systematic reviews will be used as a source of primary references for the 
guideline.  To ensure that all relevant studies are captured in the search, the 
bibliography is vetted by the content experts.  
Grading of Evidence 
First, the quality of each study is assessed using scales adapted from existing 
methodology checklists 34-38, and scores are recorded in the evidence tables. Next, the 
quality of the evidence base is assessed using methods adapted from the GRADE 
Working Group.27-30, 39 In summary, GRADE tables are developed for each of the 
interventions or questions addressed within the evidence tables. Included in the GRADE 
tables are the intervention of interest, any outcomes listed in the evidence tables that 
are judged to be clinically important by the working group, the quantity and type of 
evidence for each outcome, the relevant findings, and the GRADE of evidence for each 
outcome, as well as an overall GRADE of the evidence base for the given intervention 
or question. For therapy or harm questions, the initial GRADE of evidence for each 
outcome is deemed high if the evidence base includes an RCT or a systematic review 
of RCTs, low if the evidence base includes only observational studies, or very low if the 
evidence base consists only of descriptive studies (i.e., uncontrolled studies) or expert 
opinion.  The initial GRADE is then modified by eight criteria.  Criteria which can 
decrease the GRADE of an evidence base include poor quality of individual studies, 
inconsistent findings among studies, indirectness of study findings to the study question, 
imprecision of study estimates, and publication bias. Criteria that can increase the 
GRADE include a large magnitude of effect, a dose-response gradient, or inclusion of 
unmeasured confounders that would increase the effect size (Table 1). For questions 
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regarding diagnostic measures (e.g., sensitivity or predictive values) or descriptive 
measures (e.g., prevalence or incidence), the initial GRADE of evidence can be high 
even if the evidence base only includes descriptive study designs, like cross-sectional 
studies.30  The initial GRADE can then be modified by criteria similar to those used for 
therapy or harm questions.  GRADE definitions are as follows27, 28: 
1. High - further research is very unlikely to change confidence in the 
estimate of effect 
2. Moderate - further research is likely to affect confidence in the estimate of 
effect and may change the estimate 
3. Low - further research is very likely to affect confidence in the estimate of 
effect and is likely to change the estimate 
4. Very low - any estimate of effect is very uncertain  
After determining the GRADE of the evidence base for each outcome of a given 
intervention or question, the overall GRADE of the evidence base for that intervention or 
question is calculated. The overall GRADE is based on the lowest GRADE for the 
outcomes deemed critical by the working group to making a recommendation.  
Formulating Recommendations 
Narrative evidence summaries are then drafted by the working group using the 
evidence and GRADE tables.  One summary is written for each theme that emerges 
under each key question.  The working group then uses the narrative evidence 
summaries to develop guideline recommendations.  Factors determining the strength of 
a recommendation include29: 1) the values and preferences of the working group when 
determining which study outcomes are critical28, 2) the risks and benefits that result 
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from weighing the critical outcomes, and 3) the overall GRADE of the evidence base for 
the given intervention or question (Table 2).  If weighing the critical outcomes for a given 
intervention or question results in a "net benefit" or a "net harm", then a Category I 
Recommendation is formulated to strongly recommend for or against the given 
intervention respectively.  If weighing the critical outcomes for a given intervention or 
question results in a "trade off" between benefits and harms, then a Category II 
Recommendation is formulated to recommend that providers or institutions consider the 
intervention when deemed appropriate.  If weighing the critical outcomes for a given 
intervention or question results in an "uncertain trade off" between benefits and harms, 
then No Recommendation is formulated to reflect this uncertainty. 
For Category I recommendations, levels A and B represent the quality of the 
evidence underlying the recommendation, with A representing high to moderate quality 
evidence and B representing low to very low quality evidence but established standards 
(e.g., aseptic technique, education and training).  For Category IB recommendations, 
although there may be low to very low quality evidence directly supporting the benefits 
of the intervention, the theoretical benefits are clear, and the theoretical risks are 
marginal.  Category IC represents practices required by state or federal regulation, 
regardless of the quality of evidence.  It is important to note that the strength of a 
Category IA recommendation is equivalent to that of a Category IB or IC 
recommendation; it is only the quality of the evidence underlying the Category IA 
recommendation that makes it different from a Category IB.  
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In some instances, multiple recommendations may emerge from a single 
narrative evidence summary.  The updated HICPAC categorization scheme for 
recommendations is provided in Table 3. 
 Category I recommendations are defined as strong recommendations with the 
following implications29: 
1. For patients: Most people in the patient’s situation would want the recommended 
course of action and only a small proportion would not. Patients should request 
discussion if the intervention is not offered. 
2. For clinicians: Most patients should receive the recommended course of action. 
3. For policymakers: The recommendation may be considered for policy in many 
situations. 
Category II recommendations are defined as weak recommendations with the 
following implications29: 
1. For patients: Most people in the patient’s situation would want the recommended 
course of action, but some may not. 
2. For clinicians: Different choices will be appropriate for different patients and 
clinicians must help patients arrive at management decisions consistent with their 
values and preferences. 
3. For policymakers: Policy making requires substantial debate and involvement of 
many stakeholders. 
Our evidence-based recommendations are then cross-checked with those from 
guidelines identified in our original systematic search.  In addition, recommendations 
from previous guidelines for topics not directly addressed by our systematic review of 
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the evidence are included in a "Summary of Recommendations" if they are deemed 
critical to the target users of the guideline.  Unlike recommendations informed by the 
literature search, these recommendations are not linked to a key question.  Instead, 
these recommendations are agreed upon by expert consensus and are generally 
designated either Category IB if they represent a strong recommendation based on 
accepted practices (e.g., aseptic technique) or Category II if they are a suggestion 
based on a probable net benefit despite limited evidence. 
We carefully select the wording of each recommendation to reflect the 
recommendation's strength.40  We use the active voice when writing Category I 
recommendations - the strong recommendations.  Phrases like "do" or "do not" and 
verbs without conditionals are used to convey certainty.  A passive voice is used when 
writing Category II recommendations - the weak recommendations.  Words like 
"consider” and phrases like "is preferable,” “is suggested,” or “is not suggested” are 
used to reflect the lesser certainty of the Category II recommendations. Rather than a 
simple statement of fact, each recommendation is actionable, describing precisely a 
proposed action to take.41  
The category "No recommendation/unresolved issue" is most commonly applied 
to situations where either: 1) the overall quality of the evidence base for a given 
intervention is low to very low or 2) there is no published evidence on outcomes 
deemed critical to weighing the risks and benefits of a given intervention. If the latter is 
the case, those critical outcomes are noted at the end of the relevant evidence 
summary. 
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All recommendations are formulated to be consistent with policies from the 
United States Food and Drug Administration (FDA) and Environmental Protection 
Agency (EPA).  All recommendations are approved by HICPAC members, and focus 
only on efficacy, effectiveness, and safety.  Yet, the optimal use of these guidelines 
should include a consideration of the costs relevant to the local setting of guideline 
users.  
Reviewing and Finalizing the Guideline 
After a draft of the tables, narrative summaries, and recommendations is 
completed, the working group shares this draft with the content experts for review in 
depth.  While the content experts are reviewing this draft, the working group completes 
the remaining sections of the guideline, including the executive summary, background, 
summary of recommendations, and recommendations for guideline implementation, 
audit, and further research.  The working group then makes revisions to the draft based 
on feedback from the content experts, and presents the entire draft guideline to 
HICPAC for review.  CDC then submits the guideline for clearance, and posts it on the 
Federal Register for public comment.  After a period of public comment, the guideline is 
revised accordingly, and the final guideline is published and posted on the HICPAC 
website.   
Updating the Guideline 
Guidelines will be reassessed periodically, and general or targeted revisions to 
guidelines will be dictated by new research and technological advancements in the 




 To improve the impact of guidelines on patient care quality and safety, multiple 
implementation initiatives are underway.5  In addition, future HICPAC guidelines will 
include an implementation and audit section.  This section includes multi-modal 
implementation of specific recommendations or modules 25 that highlight the most 
critical recommendations in the guideline.24  Besides being the focus of infection 
preventionists and healthcare epidemiologists, these recommendations may also be 
ripe for integration into computerized clinical decision support systems.43  This section 
also includes performance indicators that can be used by healthcare facilities or 
regulators of such facilities to improve guideline adherence and ultimately patient care, 
and may be the focus of pay for performance contracts either locally or nationally.  
These modules and performance indicators established by HICPAC are based on the 
evidence review and recommendations.    
Looking to Future Challenges and Opportunities  
By integrating current advances in guideline development and implementation 
into future HICPAC guidelines, we believe HICPAC will be able to confront many of 
today's emerging challenges successfully.  However, there are a number of 
methodological challenges that are inadequately addressed by current advances.  
These challenges will likely be addressed by future advances, and HICPAC will stand at 
the ready to integrate these future advances into its processes.  Some such 
methodological challenges include: 1) questions for which there is little to no evidence 
upon which to base a recommendation, there is little to no requirement for evidence 
given the high prior probability of a recommendation's success 44, 45, or the evidence 
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arises from basic science studies whose strength of evidence may not be accurately 
reflected in the current approaches to grading an evidence base (this last point is 
particularly relevant to the evidence addressing infection prevention and control 
questions); 2) those inherent to using systematic reviews in a systematic review, 
including how to judge the quality of studies included in the original systematic review 33; 
3) how to use meta-analyses in guidelines effectively given the heterogeneity of 
populations, interventions and outcomes often studied to address a single question; 4) 
the role of cost analyses in recommendations, particularly given the sometimes great 
differences in the costs of drugs and devices by state and by healthcare facility 46, 47; 
and 5) the use of population based patient preference evidence to inform individual 
patient decisions 48-51.   
In addition, there are operational challenges that remain despite HICPAC's new 
approach to guideline development.  To maintain the success and efficiency of 
HICPAC's new approach, the committee may want to rely on a small cadre of HICPAC 
members and CDC staff trained and experienced in the methods of guideline 
development; however, this methods expertise must be balanced by content expertise, 
and this balance may result in a less efficient but more valid guideline development 
process.  Second, guidelines must be developed efficiently and updated regularly if they 
are to provide the most valid, relevant and up-to-date guidance, particularly in the 
context of emerging infections for which there may be a rapidly growing body of 
literature; however, this efficiency can conflict with the time often required for sufficient 
expert and public input.  Third, guideline implementation could be markedly improved 
with the development of strategies to enable automatic integration of guidelines into 
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computerized clinical decision support.43  Fourth, as highlighted by a recent report by 
the U.S. Government Accountability Office, the quantity of existing HICPAC 
recommendations is substantial and there is a need to assist providers with translation 
and prioritization of these recommendations across the continuum of care.52  Lastly, 
HICPAC will need to identify gaps in research to better prevent and control infections.  
In fact, one of the major strengths of performing a systematic review to develop a 
guideline is the ability to systematically uncover these critical evidence gaps.  These 
gaps often represent only a handful of potential research studies which, if performed, 
could provide much needed answers to our most critical questions.   
Conclusion 
The current update to HICPAC's guideline methodology builds on past strengths 
and current advances in guideline development and implementation, and enables 
HICPAC to improve the validity and usability of its guidelines while also addressing 
emerging challenges in guideline development in the area of infection prevention and 
control.  Despite the current update, methodological and operational challenges persist, 
and HICPAC is ready to integrate any future advances into its processes as 
appropriate.    
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Criteria to Decrease Grade 






Serious (-1 grade) or very 








Some (-1 grade) or major  








High risk of bias (-1 grade) 
Strong association 
Strong (+1 grade) or 
very strong evidence of 
association (+2 grades) 
 
Dose-response 
Evidence of a dose-






















Abbreviations: Grading of Recommendations Assessment, Development and Evaluation 
(GRADE); Randomized Controlled Trial (RCT).
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Table 2: Formulating Recommendations 
 
HICPAC Recommendation Weighing Benefits and Harms for Critical Outcomes Quality of Evidence 
STRONG (Category I) 
Interventions with net benefits or 
net harms 
 
Category IA – High to Moderate
 
Category IB – Low to Very Low
(Established Practice) 
 
Category IC – High to Very Low
(Regulatory)  
WEAK (Category II) 
Interventions with trade offs 
between benefits and harms 
 
High to Very Low 
No recommendation/unresolved 
Issue 
Uncertain trade offs between 




Table 3. Updated HICPAC Categorization Scheme for Recommendations 
 
Category IA 
A strong recommendation supported by high to moderate quality evidence 
suggesting net clinical benefits or harms. 
Category IB 
A strong recommendation supported by low quality evidence suggesting 
net clinical benefits or harms, or an accepted practice (e.g., aseptic 
technique) supported by low to very low quality evidence. 
Category IC A strong recommendation required by state or federal regulation. 
Category II 
A weak recommendation supported by any quality evidence suggesting a 
trade off between clinical benefits and harms. 
No 
Recommendation 
An unresolved issue for which there is low to very low quality evidence with 
uncertain trade offs between benefits and harms. 
 







Figure 2. The Guideline Development Process 
                                   
GUIDELINE SEARCH
DEVELOPMENT OF KEY QUESTIONS
Relevant guidelines reviewed to inform key questions
LITERATURE SEARCH
Databases identified; search strategy developed; 
references stored; duplicates resolved
ABSTRACT AND FULL-TEXT REVIEW
Relevant studies identified
DATA EXTRACTION AND SYNTHESIS
Data abstracted into evidence tables; study quality 
assessed
DRAFT RECOMMENDATIONS
Strength of evidence graded; summaries and 
recommendations drafted
FINALIZE RECOMMENDATIONS
Federal Register posting and public comment; 
recommendations finalized; final vote; guideline published  
 
 
 31
